Peripheral blood haplo-SCT feasible for leukemia patients 70 years and older

For sufferers with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) utilizing a nonmyeloablative conditioning routine (NMAC) is possible, with no early nonrelapse mortality (NRM), in accordance with a research printed on-line Nov. 3 in Bone Marrow Transplantation.

Samia Harbi, M.D., from the Institut Paoli-Calmettes in Marseille, France, and colleagues reported a single-center expertise of peripheral blood Haplo-SCT with NMAC and posttransplantation cyclophosphamide in 50 sufferers aged 70 years and older with AML and MDS (27 and 23, respectively). Twenty-four % of the sufferers had lively illness at Haplo-SCT.

The researchers discovered that the cumulative incidence was 6 and 25 % for grade 3 to 4 acute and moderate-to-severe persistent graft-versus-host illness (GVHD), respectively. At day +100, NRM was 0 %. At three years, NRM, relapse, progression-free survivaland general survival have been 16, 18, 66, and 69 %, respectively. Eighty-eight % of sufferers who have been disease-free at two years after Haplo-SCT have been dwelling with out immunosuppressive therapy.

“We conclude that in extremely chosen sufferers ≥70 years, NMAC Haplo-SCT with peripheral blood stem cell and posttransplantation cyclophosphamide may be very effectively tolerated and allowed long-term survival in AML or MDS patients with out persistent persistent GVHD,” the authors write.

Copyright © 2023 HealthDay. All rights reserved.